Irradiated wild-type and Spa mutant Staphylococcus aureus induce anti-S. aureus immune responses in mice which do not protect against subsequent intravenous challenge

Pathogens and Disease

Volumn 68, Issue 1, 2013, Pages 20-26

  Van Diemen, Pauline M ^a   Yamaguchi, Yuko ^a   Paterson, Gavin K ^a,b   Rollier, Christine S ^a   Hill, Adrian V S ^a   Wyllie, David H ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Antibacterial antibodies; I.v. challenge; Spa; Staphylococcus aureus; Vaccine; irradiation

Indexed keywords

BACTERIUM ANTIBODY; CELL SURFACE PROTEIN; STAPHYLOCOCCUS AUREUS ANTIBODY; UNCLASSIFIED DRUG; BACTERIAL ANTIGEN; STAPHYLOCOCCUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BACTERIAL COUNT; BACTERIAL LOAD; CONTROLLED STUDY; FEMALE; GAMMA IRRADIATION; IMMUNOASSAY; IMMUNOGENICITY; INTRAVENOUS ADMINISTRATION; KIDNEY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTECTION; SOLITARY KIDNEY; STAPHYLOCOCCUS AUREUS; VACCINATION; ANIMAL; BAGG ALBINO MOUSE; BLOOD; DISEASE MODEL; GAMMA RADIATION; GENETICS; IMMUNOLOGY; MICROBIAL VIABILITY; MICROBIOLOGY; RADIATION RESPONSE; STAPHYLOCOCCAL INFECTIONS; RADIATION EXPOSURE; STAPHYLOCOCCUS INFECTION;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; DISEASE MODELS, ANIMAL; FEMALE; GAMMA RAYS; KIDNEY; MICE; MICE, INBRED BALB C; MICROBIAL VIABILITY; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCAL VACCINES; STAPHYLOCOCCUS AUREUS;

EID: 84899467091     PISSN: None     EISSN: 2049632X     Source Type: Journal    
DOI: 10.1111/2049-632X.12042     Document Type: Article

References (38)

1. Bain RK (1999) Irradiated vaccines for helminth control in livestock. Int J Parasitol 29: 185-191.
2. Burbelo PD, Goldman R & Mattson TL (2005) A simplified immunoprecipitation method for quantitatively measuring antibody responses in clinical sera samples by using mammalian-produced Renilla luciferase-antigen fusion proteins. BMC Biotechnol 5: 22.
3. Burnside K, Lembo A, Harrell MI, Klein JA, Lopez-Guisa J, Siegesmund AM, Torgerson TR, Oukka M, Molina DM & Rajagopal L (2012) Vaccination with a UV-irradiated genetically attenuated mutant of Staphylococcus aureus provides protection against subsequent systemic infection. J Infect Dis 206: 1734-1744.
4. Burts ML, Williams WA, DeBord K & Missiakas DM (2005) EsxA and EsxB are secreted by an ESAT-6-like system that is required for the pathogenesis of Staphylococcus aureus infections. P Natl Acad Sci USA 102: 1169-1174.
5. Cheng AG, Kim HK, Burts ML, Krausz T, Schneewind O & Missiakas DM (2009) Genetic requirements for Staphylococcus aureus abscess formation and persistence in host tissues. FASEB J 23: 3393-3404.
6. Clarke SR & Foster SJ (2008) IsdA protects Staphylococcus aureus against the bactericidal protease activity of apolactoferrin. Infect Immun 76: 1518-1526.
7. Datta SK, Okamoto S, Hayashi T, Shin SS, Mihajlov I, Fermin A, Guiney DG, Fierer J & Raz E (2006) Vaccination with irradiated Listeria induces protective T cell immunity. Immunity 25: 143-152.
8. Datta SK, Sabet M, Nguyen KP et al. (2010) Mucosal adjuvant activity of cholera toxin requires Th17 cells and protects against inhalation anthrax. P Natl Acad Sci USA 107: 10638-10643.
9. DeJonge M, Burchfield D, Bloom B et al. (2007) Clinical trial of safety and efficacy of INH-A21 for the prevention of nosocomial staphylococcal bloodstream infection in premature infants. J Pediatr 151: 260-265, 265 e261.
10. Draper SJ, Moore AC, Goodman AL, Long CA, Holder AA, Gilbert SC, Hill F & Hill AV (2008) Effective induction of high-titer antibodies by viral vector vaccines. Nat Med 14: 819-821.
11. Eisenberg GH Jr & Osterman JV (1979) Gamma-irradiated scrub typhus immunogens: broad-spectrum immunity with combinations of rickettsial strains. Infect Immun 26: 131-136.
12. Epstein JE, Tewari K, Lyke KE et al. (2011) Live attenuated malaria vaccine designed to protect through hepatic CD8(+) T cell immunity. Science 334: 475-480.
13. Garzoni C & Kelley WL (2009) Staphylococcus aureus: new evidence for intracellular persistence. Trends Microbiol 17: 59-65.
14. Gilbert SC, Schneider J, Hannan CM, Hu JT, Plebanski M, Sinden R & Hill AV (2002) Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes. Vaccine 20: 1039-1045.
15. Huang SS, Hinrichsen VL, Datta R, Spurchise L, Miroshnik I, Nelson K & Platt R (2011) Methicillin-resistant Staphylococcus aureus infection and hospitalization in high-risk patients in the year following detection. PLoS ONE 6: e24340.
16. Jerrells TR, Palmer BA & Osterman JV (1983) Gamma-irradiated scrub typhus immunogens: development of cell-mediated immunity after vaccination of inbred mice. Infect Immun 39: 262-269.
17. Johnson AP (2011) Methicillin-resistant Staphylococcus aureus: the European landscape. J Antimicrob Chemother 66(suppl 4): iv43-iv48.
18. Johnson NV, Ahn SH, Deshmukh H, Levin MK, Nelson CL, Scott WK, Allen A, Fowler VG Jr & Cowell LG (2012) Haplotype Association Mapping Identifies a Candidate Gene Region in Mice Infected with Staphylococcus aureus. G3 (Bethesda) 2: 693-700.
19. Jongerius I, Puister M, Wu J, Ruyken M, van Strijp JA & Rooijakkers SH (2010) Staphylococcal complement inhibitor modulates phagocyte responses by dimerization of convertases. J Immunol 184: 420-425.
20. Katinger A, Lubitz W, Szostak MP, Stadler M, Klein R, Indra A, Huter V & Hensel A (1999) Pigs aerogenously immunized with genetically inactivated (ghosts) or irradiated Actinobacillus pleuropneumoniae are protected against a homologous aerosol challenge despite differing in pulmonary cellular and antibody responses. J Biotechnol 73: 251-260.
21. Kim HK, Cheng AG, Kim HY, Missiakas DM & Schneewind O (2010a) Nontoxigenic protein A vaccine for methicillin-resistant Staphylococcus aureus infections in mice. J Exp Med 207: 1863-1870.
22. Kim HK, Dedent A, Cheng AG, McAdow M, Bagnoli F, Missiakas DM & Schneewind O (2010b) IsdA and IsdB antibodies protect mice against Staphylococcus aureus abscess formation and lethal challenge. Vaccine 28: 6382-6392.
23. Kim HK, Kim HY, Schneewind O & Missiakas D (2011) Identifying protective antigens of Staphylococcus aureus, a pathogen that suppresses host immune responses. FASEB J 25: 3605-3612.
24. Kozlowski LM, Li W, Goldschmidt M & Levinson AI (1998) In vivo inflammatory response to a prototypic B cell superantigen: elicitation of an Arthus reaction by staphylococcal protein A. J Immunol 160: 5246-5252.
25. Magnani DM, Harms JS, Durward MA & Splitter GA (2009) Nondividing but metabolically active gamma-irradiated Brucella melitensis is protective against virulent B. melitensis challenge in mice. Infect Immun 77: 5181-5189.
26. McDevitt D, Francois P, Vaudaux P & Foster TJ (1995) Identification of the ligand-binding domain of the surface-located fibrinogen receptor (clumping factor) of Staphylococcus aureus. Mol Microbiol 16: 895-907.
27. Ni Eidhin D, Perkins S, Francois P, Vaudaux P, Hook M & Foster TJ (1998) Clumping factor B (ClfB), a new surface-located fibrinogen-binding adhesin of Staphylococcus aureus. Mol Microbiol 30: 245-257.
28. Noskin GA, Rubin RJ, Schentag JJ, Kluytmans J, Hedblom EC, Jacobson C, Smulders M, Gemmen E & Bharmal M (2007) National trends in Staphylococcus aureus infection rates: impact on economic burden and mortality over a 6-year period (1998-2003). Clin Infect Dis 45: 1132-1140.
29. Schaffer AC, Solinga RM, Cocchiaro J et al. (2006) Immunization with Staphylococcus aureus clumping factor B, a major determinant in nasal carriage, reduces nasal colonization in a murine model. Infect Immun 74: 2145-2153.
30. Schmaler M, Jann NJ, Ferracin F & Landmann R (2011) T and B cells are not required for clearing Staphylococcus aureus in systemic infection despite a strong TLR2-MyD88-dependent T cell activation. J Immunol 186: 443-452.
31. Suree N, Liew CK, Villareal VA, Thieu W, Fadeev EA, Clemens JJ, Jung ME & Clubb RT (2009) The structure of the Staphylococcus aureus sortase-substrate complex reveals how the universally conserved LPXTG sorting signal is recognized. J Biol Chem 284: 24465-24477.
32. Thomsen I, Dudney H & Creech CB (2010) Searching for the holy grail of a staphylococcal vaccine. Hum Vaccin 6: 1068-1070.
33. Thwaites GE & Gant V (2011) Are bloodstream leukocytes Trojan Horses for the metastasis of Staphylococcus aureus? Nat Rev Microbiol 9: 215-222.
34. Tuchscherr L, Medina E, Hussain M et al. (2011) Staphylococcus aureus phenotype switching: an effective bacterial strategy to escape host immune response and establish a chronic infection. EMBO Mol Med 3: 129-141.
35. van Belkum A, Verkaik NJ, de Vogel CP, Boelens HA, Verveer J, Nouwen JL, Verbrugh HA & Wertheim HF (2009) Reclassification of Staphylococcus aureus nasal carriage types. J Infect Dis 199: 1820-1826.
36. Verkaik NJ, de Vogel CP, Boelens HA et al. (2009) Anti-staphylococcal humoral immune response in persistent nasal carriers and noncarriers of Staphylococcus aureus. J Infect Dis 199: 625-632.
37. Verkaik NJ, Boelens HA, de Vogel CP, Tavakol M, Bode LG, Verbrugh HA, van Belkum A & van Wamel WJ (2010) Heterogeneity of the humoral immune response following Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis 29: 509-518.
38. Wertheim HF, Vos MC, Ott A, van Belkum A, Voss A, Kluytmans JA, van Keulen PH, Vandenbroucke-Grauls CM, Meester MH & Verbrugh HA (2004) Risk and outcome of nosocomial Staphylococcus aureus bacteraemia in nasal carriers versus non-carriers. Lancet 364: 703-705.